ES2172303T3 - Agentes terapeuticos obtenidos por catalisis enzimatica. - Google Patents

Agentes terapeuticos obtenidos por catalisis enzimatica.

Info

Publication number
ES2172303T3
ES2172303T3 ES99904195T ES99904195T ES2172303T3 ES 2172303 T3 ES2172303 T3 ES 2172303T3 ES 99904195 T ES99904195 T ES 99904195T ES 99904195 T ES99904195 T ES 99904195T ES 2172303 T3 ES2172303 T3 ES 2172303T3
Authority
ES
Spain
Prior art keywords
therapeutic agents
agents obtained
enzymatic catalysis
catalysis
enzymatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99904195T
Other languages
English (en)
Inventor
H Michael Shepard
Michael P Groziak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celmed Oncology USA Inc
Original Assignee
Newbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc filed Critical Newbiotics Inc
Application granted granted Critical
Publication of ES2172303T3 publication Critical patent/ES2172303T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compuesto que tiene la estructura: o una de sus sales, éteres o ésteres farmacéuticamente aceptables.
ES99904195T 1998-01-23 1999-01-22 Agentes terapeuticos obtenidos por catalisis enzimatica. Expired - Lifetime ES2172303T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7226498P 1998-01-23 1998-01-23
US7695098P 1998-03-05 1998-03-05
US10863498P 1998-11-16 1998-11-16

Publications (1)

Publication Number Publication Date
ES2172303T3 true ES2172303T3 (es) 2002-09-16

Family

ID=27372051

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99904195T Expired - Lifetime ES2172303T3 (es) 1998-01-23 1999-01-22 Agentes terapeuticos obtenidos por catalisis enzimatica.

Country Status (16)

Country Link
US (3) US6339151B1 (es)
EP (2) EP1045897B1 (es)
JP (2) JP2002500880A (es)
CN (1) CN1192102C (es)
AT (1) ATE212661T1 (es)
AU (1) AU753155B2 (es)
BR (1) BR9907736A (es)
CA (1) CA2317505C (es)
DE (1) DE69900841T2 (es)
DK (1) DK1045897T3 (es)
ES (1) ES2172303T3 (es)
HK (1) HK1039520A1 (es)
IL (1) IL137164A0 (es)
PT (1) PT1045897E (es)
TW (1) TWI244924B (es)
WO (1) WO1999037753A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11502515A (ja) 1995-02-01 1999-03-02 フラウンホファー−ゲゼルシャフト・ツァ・フェルダリュング・デア・アンゲバンテン・フォルシュング・エー・ファウ 細胞増殖抑制剤処理における耐性形成に対する５’置換ヌクレオシドの利用と、このヌクレオシドを含む医薬品
ATE413881T1 (de) * 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) * 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CN1390227A (zh) * 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
JP2003527317A (ja) * 1999-07-22 2003-09-16 ニューバイオティックス インコーポレイテッド 酵素触媒抗感染性治療剤
AU774492B2 (en) * 1999-07-22 2004-07-01 Celmed Oncology (Usa) Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets
US20030130179A1 (en) * 2000-07-20 2003-07-10 Shepard H. Michael Methods for identifying therapeutic targets for treating infectious disease
CZ304734B6 (cs) * 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
EP1359921A4 (en) * 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
WO2002089739A2 (en) * 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US20030212147A1 (en) * 2001-07-12 2003-11-13 Chung Sum Man Stephen Enzyme activated chemotherapy of liver cancer
BR0211900A (pt) * 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
YU44404A (sh) * 2001-11-23 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Postupak za identifikovanje ciljnih enzima tumora
US20030152747A1 (en) * 2002-01-11 2003-08-14 The Garland Company, Inc., An Ohio Corporation Roofing materials
CN1662238A (zh) * 2002-04-18 2005-08-31 塞米得肿瘤学美国公司 肽去甲酰酶活化的前体药物
WO2004043400A2 (en) 2002-11-14 2004-05-27 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
EP1599484A2 (en) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
AU2004248138B2 (en) * 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2005027962A1 (en) * 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
RU2413731C2 (ru) * 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006110531A2 (en) * 2005-04-07 2006-10-19 Health Research Inc. Acyl homoserine lactones for inhibition of cell growth
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG194404A1 (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102481334B (zh) 2009-06-22 2013-12-18 健康研究股份有限公司 前药抗癌治疗
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
KR102077871B1 (ko) * 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
CN103501824A (zh) * 2011-02-18 2014-01-08 Uab研究基金会 与嘌呤核苷磷酸化酶或核苷水解酶的前体药物的改进的治疗用途相关的应用
HUE029022T2 (en) * 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201503750YA (en) 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US9828409B2 (en) * 2014-03-19 2017-11-28 Minghong Zhong Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
US10071112B2 (en) 2014-10-08 2018-09-11 Epigenetics Pharma Llc Vitamin E-nucleoside prodrugs
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN109207551B (zh) * 2017-07-07 2023-05-26 上海睿智化学研究有限公司 一种筛选叶酸代谢相关药物的方法
KR102545956B1 (ko) * 2022-10-19 2023-06-22 주식회사 카이팜 브리부딘을 유효성분으로 포함하는 오스카 유도 질환의 예방 또는 치료용 조성물

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB982776A (en) * 1962-01-24 1965-02-10 Wellcome Found 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity
JPS5017989B1 (es) * 1970-12-24 1975-06-25
US4247544A (en) 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
JPS5843993A (ja) 1981-09-09 1983-03-14 Yamasa Shoyu Co Ltd １−β−Ｄ−アラビノフラノシル−（Ｅ）−５−（２−ハロゲノビニル）ウラシル−５′−りん酸およびその製造法
EP0095294A1 (en) 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
DE3229169A1 (de) 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Verwendung von 5-alkylpyrimidinnukleosiden und deren derivate als zytostatika
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
RO88451A2 (ro) 1984-06-05 1986-01-30 Intreprinderea De Antibiotice,Ro Derivati ai acidului 7-aminocefalosporanic si procedeu de preparare aacestora
US5212291A (en) 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
US5077283A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US5077282A (en) * 1986-10-23 1991-12-31 American Cyanamid Company Solubilized pro-drugs
US5116827A (en) 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5070082A (en) * 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US4963533A (en) 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5116822A (en) 1986-10-24 1992-05-26 Stichting Rega Vzw Therapeutic application of dideoxycytidinene
NL8700366A (nl) 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5085983A (en) 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0311108A3 (en) 1987-10-08 1990-04-04 Stichting REGA V.Z.W. Anti-hiv active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5217869A (en) 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5300425A (en) 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US4963263A (en) 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5338659A (en) 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
EP0316592A3 (en) 1987-11-13 1990-09-19 Stichting REGA V.Z.W. 3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application
CA1317291C (en) 1987-12-14 1993-05-04 Naeem Botros Hanna Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds
DE68917479D1 (de) * 1988-02-24 1994-09-15 Inst Rech Chim Biolog Derivate von deoxy-2'-uridin substituiert in der 5, 3' oder 5' stellung durch acylierte alpha-amino-gruppen, verfahren zur herstellung und arzneimittel daraus.
WO1990003978A1 (en) 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
US5596018A (en) 1988-12-28 1997-01-21 Toray Industries, Inc. Antiviral agents against aids-causing virus
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
GB9010242D0 (en) 1990-05-08 1990-06-27 British Telecomm Optical signal regenerator and optical communications system incorporating same
US5137724A (en) 1990-05-23 1992-08-11 Stichting Rega Vzw Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
DE69227594D1 (de) 1991-04-29 1998-12-17 Terrapin Tech Inc Verfahren zur erkennung und behandlung anomaler zellen
US5556942A (en) 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
WO1992020344A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
ES2087962T3 (es) 1991-09-04 1996-08-01 Stichting Rega V Z W Derivados nucleosidos sustituidos, metodos para su preparacion y composiciones farmaceuticas que los contienen.
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5274162A (en) 1991-12-13 1993-12-28 Arnold Glazier Antineoplastic drugs with bipolar toxification/detoxification functionalities
KR940703677A (ko) * 1991-12-31 1994-12-12 토루 페더슨 약물내성 말라리아에 대해 활성인 항기생충 올리고누클레오티드(antipar-asitic oligonucleotides active against drug resistant malaria)
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5668828A (en) * 1992-05-08 1997-09-16 Sanconix, Inc. Enhanced frequency agile radio
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US5502037A (en) 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
DE69425379T2 (de) 1993-09-21 2000-11-30 Amersham Pharmacia Biotech Uk Ltd., Little Chalfont Elongation, amplifikation und sequenzierung unter verwendung eines chimären oligonucleotids
US5908919A (en) 1993-10-01 1999-06-01 Terrapin Technologies Urethane mediated, GST specific molecular release systems
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5521161A (en) 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5556992A (en) * 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5968910A (en) 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
JPH11502515A (ja) 1995-02-01 1999-03-02 フラウンホファー−ゲゼルシャフト・ツァ・フェルダリュング・デア・アンゲバンテン・フォルシュング・エー・ファウ 細胞増殖抑制剤処理における耐性形成に対する５’置換ヌクレオシドの利用と、このヌクレオシドを含む医薬品
US5705336A (en) 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
IN186549B (es) 1995-04-19 2001-09-29 Kumiai Chemical Co Ltd
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5998151A (en) 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
WO1997021452A2 (en) 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
US5880097A (en) 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US6149904A (en) * 1996-01-31 2000-11-21 The Regents Of The University Of California Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
WO1999006072A1 (en) 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
ATE413881T1 (de) * 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
AU729377B2 (en) * 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
AU758426B2 (en) 1997-10-30 2003-03-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleosides for imaging and treatment applications
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB9821121D0 (en) 1998-09-29 1998-11-25 James Robinson Ltd Grey colouring photochromic fused pyrans
PT1144011E (pt) 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
CN1390227A (zh) * 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2001007888A2 (en) 1999-07-23 2001-02-01 Westinghouse Electric Company Llc Pulsed gamma neutron activation analysis (pgnaa) method and apparatus for nondestructive assay of containerized contaminants
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
US20020147175A1 (en) * 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
EP1359921A4 (en) * 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Also Published As

Publication number Publication date
EP1045897A4 (en) 2000-10-25
JP2002500880A (ja) 2002-01-15
EP1167972A2 (en) 2002-01-02
US7601703B2 (en) 2009-10-13
EP1045897A1 (en) 2000-10-25
JP2001220397A (ja) 2001-08-14
EP1167972B1 (en) 2017-03-08
US6245750B1 (en) 2001-06-12
HK1039520A1 (en) 2002-04-26
DK1045897T3 (da) 2002-05-13
AU753155B2 (en) 2002-10-10
BR9907736A (pt) 2000-10-17
EP1167972A3 (en) 2006-05-24
CN1291228A (zh) 2001-04-11
US6339151B1 (en) 2002-01-15
TWI244924B (en) 2005-12-11
DE69900841T2 (de) 2002-10-02
DE69900841D1 (de) 2002-03-14
IL137164A0 (en) 2001-07-24
EP1045897B1 (en) 2002-01-30
CN1192102C (zh) 2005-03-09
ATE212661T1 (de) 2002-02-15
AU2464699A (en) 1999-08-09
WO1999037753A1 (en) 1999-07-29
CA2317505A1 (en) 1999-07-29
PT1045897E (pt) 2002-07-31
US20010034440A1 (en) 2001-10-25
HK1030624A1 (en) 2001-05-11
CA2317505C (en) 2011-01-04
JP3265304B2 (ja) 2002-03-11

Similar Documents

Publication Publication Date Title
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
TR199901077A2 (en) �spen�iyari form�lasyonlar.
PT1193270E (pt) Pirrolobenzodiazepinas
BRPI0010891B1 (pt) geração de microespuma terapêutica.
MXPA02007915A (es) Mediador de lipido activado por aspirina.
HRP20041084B1 (hr) C-aril glukozid inhibitori sglt2 i postupak
TR200000782T2 (tr) Resorsinol türevleri.
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
IT1302347B1 (it) Procedimento per la produzione diretta di perossido di idrogeno.
ES2195970T3 (es) L-ribavirina y usos de la misma.
AR015379A1 (es) Ascorbil-fosforil-colesterol
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
NO954768D0 (no) N-alkyltiopolyaminderivater som radiobeskyttende midler
NO994822D0 (no) Immunotolerant protrombinkomplekspreparat
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
BR0007922A (pt) Compostos calcilìticos
DK1073447T3 (da) N1-modificerede glycopeptider
IT1318575B1 (it) Procedimento integrato per la produzione di cumene.
UY26574A1 (es) " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol".
ES2173586T3 (es) Derivados de ciclohexandiol.
AR027349A1 (es) Derivados de amidas heterociclicas
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1045897

Country of ref document: ES